Is Fitbit in Trouble With Apple’s New Watch?

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Is Fitbit in Trouble With Apple’s New Watch?

© Apple.com

Fitbit Inc. (NYSE: FIT) shares bounced back in Thursday’s session after posting a loss of nearly 7% on Wednesday in regards to the Apple Inc. (NASDAQ: AAPL) presentation for its fall product lineup. Most of this drop centered on the new Apple Watch, which could pose a threat to Fitbit.

Apple’s newest smartwatch, which starts retailing at $399, can now perform an electrocardiogram (ECG) and detect atrial fibrillation or when a person’s heart rate is too low. This watch is even approved by the U.S. Food and Drug Administration (FDA) for direct-to-consumer purchase, which is a first for over-the-counter ECG-enabled devices.

The new Apple Watch will be available for preorder on September 14, and it will begin selling on September 21.

Morgan Stanley’s Yuuji Anderson jumped after this presentation and weighed in on the Apple/Fitbit relationship. Overall, he believes that the drop in Fitbit’s shares on Wednesday rightly reflected the concerns over the pace of software and sensor improvements, when compared to the Fitbit ecosystem.

[nativounit]

As a result, Anderson issued an Underweight rating with a $4 price target for Fitbit, implying a downside of 27.7% from Wednesday’s closing price of $5.53. He went on to say in his report:

We are more concerned that the health and fitness functionalities between the Versa and Charge 3 are not sufficiently differentiated to avoid cannibalization and its aggregate demand will not sufficiently offset legacy product declines exiting the year,

Shares of Fitbit were up 1.6% at $5.62 in Thursday’s session. The stock has a consensus analyst price target of $6.35 and a 52-week trading range of $4.51 to $7.79.

Apple traded up about 3% to $227.57, in a 52-week range of $149.16 to $229.67. The consensus price target is $222.42.

[recirclink id=491936]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618